TABLE C-1 Dietary Reference Intakes: Estimated Average Requirements
|
Life Stage Group |
Vitamin A (µg/d)a |
Vitamin C (mg/d) |
Vitamin E (mg/d)b |
Thiamin (mg/d) |
Riboflavin (mg/d) |
Niacin (mg/d)c |
Vitamin B6 (mg/d) |
Folate (µg/d)d |
|
Infants |
|
|||||||
|
7–12 mo |
|
|||||||
|
Children |
|
|||||||
|
1–3 y |
210 |
13 |
5 |
0.4 |
0.4 |
5 |
0.4 |
120 |
|
4–8 y |
275 |
22 |
6 |
0.5 |
0.5 |
6 |
0.5 |
160 |
|
Males |
|
|||||||
|
9–13 y |
445 |
39 |
9 |
0.7 |
0.8 |
9 |
0.8 |
250 |
|
14–18 y |
630 |
63 |
12 |
1.0 |
1.1 |
12 |
1.1 |
330 |
|
19–30 y |
625 |
75 |
12 |
1.0 |
1.1 |
12 |
1.1 |
320 |
|
31–50 y |
625 |
75 |
12 |
1.0 |
1.1 |
12 |
1.1 |
320 |
|
51–70 y |
625 |
75 |
12 |
1.0 |
1.1 |
12 |
1.4 |
320 |
|
> 70 y |
625 |
75 |
12 |
1.0 |
1.1 |
12 |
1.4 |
320 |
|
Females |
|
|||||||
|
9–13 y |
420 |
39 |
9 |
0.7 |
0.8 |
9 |
0.8 |
250 |
|
14–18 y |
485 |
56 |
12 |
0.9 |
0.9 |
11 |
1.0 |
330 |
|
19–30 y |
500 |
60 |
12 |
0.9 |
0.9 |
11 |
1.1 |
320 |
|
31–50 y |
500 |
60 |
12 |
0.9 |
0.9 |
11 |
1.1 |
320 |
|
51–70 y |
500 |
60 |
12 |
0.9 |
0.9 |
11 |
1.3 |
320 |
|
> 70 y |
500 |
60 |
12 |
0.9 |
0.9 |
11 |
1.3 |
320 |
|
Pregnancy |
|
|||||||
|
14–18 y |
530 |
66 |
12 |
1.2 |
1.2 |
14 |
1.6 |
520 |
|
19–30 y |
550 |
70 |
12 |
1.2 |
1.2 |
14 |
1.6 |
520 |
|
31–50 y |
550 |
70 |
12 |
1.2 |
1.2 |
14 |
1.6 |
520 |
|
Lactation |
|
|||||||
|
14–18 y |
880 |
96 |
16 |
1.2 |
1.3 |
13 |
1.7 |
450 |
|
19–30 y |
900 |
100 |
16 |
1.2 |
1.3 |
13 |
1.7 |
450 |
|
31–50 y |
900 |
100 |
16 |
1.2 |
1.3 |
13 |
1.7 |
450 |
|
NOTE: This table presents EARs, which serve two purposes: for assessing adequacy of population intakes and as the basis for calculating Recommended Dietary Allowances (RDAs) for individuals for those nutrients. EARs have not been established for vitamin D, vitamin K, pantothenic acid, biotin, choline, calcium, chromium, fluoride, manganese, or other nutrients not yet evaluated via the DRI process. a As retinol activity equivalents (RAE). 1 RAE = 1 μg retinol, 12 μg β-carotene, 24 μg α-carotene, or 24 μg β-cryptoxanthin. The RAE for dietary provitamin A carotenoids is twofold greater than retinol equivalents (RE), whereas the RAE for preformed vitamin A is the same as RE. b As α-tocopherol. α-Tocopherol includes RRR-α-tocopherol, the only form of α-tocopherol that occurs naturally in foods, and the 2R-stereoisomeric forms of α-tocopherol (RRR-, RSR-, RRS-, and RSS-α-tocopherol) that occur in fortified foods and supplements. It does not include the 2S-stereoisomeric forms of α-tocopherol (SRR-, SSR-, SRS-, and SSS-α-tocopherol), also found in fortified foods and supplements. |
||||||||
TABLE C-2 Dietary Reference Intakes: Recommended Intakes for Individuals, Vitamins
|
Life Stage Group |
Vitamin A (μg/d)a |
Vitamin C (mg/d) |
Vitamin E (mg/d)d |
Vitamin K (μg/d) |
Thiamin (mg/d) |
|
|
Infants |
|
|||||
|
0–6 mo |
400* |
40* |
5* |
4* |
2.0* |
0.2* |
|
7–12 mo |
500* |
50* |
5* |
5* |
2.5* |
0.3* |
|
Children |
|
|||||
|
1–3 y |
300 |
15 |
5* |
6 |
30* |
0.5 |
|
4–8 y |
400 |
25 |
5* |
7 |
55* |
0.6 |
|
Males |
|
|||||
|
9–13 y |
600 |
45 |
5* |
11 |
60* |
0.9 |
|
14–18 y |
900 |
75 |
5* |
15 |
75* |
1.2 |
|
19–30 y |
900 |
90 |
5* |
15 |
120* |
1.2 |
|
31–50 y |
900 |
90 |
5* |
15 |
120* |
1.2 |
|
51–70 y |
900 |
90 |
10* |
15 |
120* |
1.2 |
|
> 70 y |
900 |
90 |
15* |
15 |
120* |
1.2 |
|
Females |
|
|||||
|
9–13 y |
600 |
45 |
5* |
11 |
60* |
0.9 |
|
14–18 y |
700 |
65 |
5* |
15 |
75* |
1.0 |
|
19–30 y |
700 |
75 |
5* |
15 |
90* |
1.1 |
|
31–50 y |
700 |
75 |
5* |
15 |
90* |
1.1 |
|
51–70 y |
700 |
75 |
10* |
15 |
90* |
1.1 |
|
> 70 y |
700 |
75 |
15* |
15 |
90* |
1.1 |
|
Pregnancy |
|
|||||
|
14–18 y |
750 |
80 |
5* |
15 |
75* |
1.4 |
|
19–30 y |
770 |
85 |
5* |
15 |
90* |
1.4 |
|
31–50 y |
770 |
85 |
5* |
15 |
90* |
1.4 |
|
Lactation |
|
|||||
|
14–18 y |
1,200 |
115 |
5* |
19 |
75* |
1.4 |
|
19–30 y |
1,300 |
120 |
5* |
19 |
90* |
1.4 |
|
31–50 y |
1,300 |
120 |
5* |
19 |
90* |
1.4 |
|
NOTE: This table (taken from the DRI reports, see www.nap.edu) presents Recommended Dietary Allowances (RDAs) in bold type and Adequate Intakes (AIs) in ordinary type followed by an asterisk (*). RDAs and AIs may both be used as goals for individual intake. RDAs are set to meet the needs of almost all (97 to 98 percent) individuals in a group. For healthy breastfed infants, the AI is the mean intake. The AI for other life stage and gender groups is believed to cover needs of all individuals in the group, but lack of data or uncertainty in the data prevents being able to specify with confidence the percentage of individuals covered by this intake. aAs retinol activity equivalents (RAEs). 1 RAE = 1 μg retinol, 12 μg β-carotene, 24 μg α-carotene, or 24 μg β-cryptoxanthin. To calculate RAEs from REs of provitamin A carotenoids in foods, divide the REs by 2. For preformed vitamin A in foods or supplements and for provitamin A carotenoids in supplements, 1 RE = 1 RAE. bAs calciferol. 1 μg calciferol = 40 IU vitamin D. cIn the absence of adequate exposure to sunlight. dAs α-tocopherol. α-Tocopherol includes RRR-α-tocopherol, the only form of α-tocopherol that occurs naturally in foods, and the 2R-stereoisomeric forms of α-tocopherol (RRR-, RSR-, RRS-, and RSS-α-tocopherol) that occur in fortified foods and supplements. It does not include the 2S-stereoisomeric forms of α-tocopherol (SRR-, SSR-, SRS-, and SSS-α-tocopherol), also found in fortified foods and supplements. |
||||||
|
Riboflavin (mg/d) |
Niacin (mg/d)e |
Vitamin B6 (mg/d) |
Folate (μg/d)f |
Vitamin B12 (μg/d) |
Pantothenic Acid (mg/d) |
Biotin (μg/d) |
Choline (mg/d)g |
|
|
|||||||
|
0.3* |
2* |
0.1* |
65* |
0.4* |
1.7* |
5* |
125* |
|
0.4* |
4* |
0.3* |
80* |
0.5* |
1.8* |
6* |
150* |
|
|
|||||||
|
0.5 |
6 |
0.5 |
150 |
0.9 |
2* |
8* |
200* |
|
0.6 |
8 |
0.6 |
200 |
1.2 |
3* |
12* |
250* |
|
|
|||||||
|
0.9 |
12 |
1.0 |
300 |
1.8 |
4* |
20* |
375* |
|
1.3 |
16 |
1.3 |
400 |
2.4 |
5* |
25* |
550* |
|
1.3 |
16 |
1.3 |
400 |
2.4 |
5* |
30* |
550* |
|
1.3 |
16 |
1.3 |
400 |
2.4 |
5* |
30* |
550* |
|
1.3 |
16 |
1.7 |
400 |
2.4h |
5* |
30* |
550* |
|
1.3 |
16 |
1.7 |
400 |
2.4h |
5* |
30* |
550* |
|
|
|||||||
|
0.9 |
12 |
1.0 |
300 |
1.8 |
4* |
20* |
375* |
|
1.0 |
14 |
1.2 |
400i |
2.4 |
5* |
25* |
400* |
|
1.1 |
14 |
1.3 |
400i |
2.4 |
5* |
30* |
425* |
|
1.1 |
14 |
1.3 |
400i |
2.4 |
5* |
30* |
425* |
|
1.1 |
14 |
1.5 |
400 |
2.4h |
5* |
30* |
425* |
|
1.1 |
14 |
1.5 |
400 |
2.4h |
5* |
30* |
425* |
|
|
|||||||
|
1.4 |
18 |
1.9 |
600j |
2.6 |
6* |
30* |
450* |
|
1.4 |
18 |
1.9 |
600j |
2.6 |
6* |
30* |
450* |
|
1.4 |
18 |
1.9 |
600j |
2.6 |
6* |
30* |
450* |
|
|
|||||||
|
1.6 |
17 |
2.0 |
500 |
2.8 |
7* |
35* |
550* |
|
1.6 |
17 |
2.0 |
500 |
2.8 |
7* |
35* |
550* |
|
1.6 |
17 |
2.0 |
500 |
2.8 |
7* |
35* |
550* |
|
eAs niacin equivalents (NE). 1 mg of niacin = 60 mg of tryptophan; 0–6 months = preformed niacin (not NE). fAs dietary folate equivalents (DFE). 1 DFE = 1 μg food folate = 0.6 μg of folic acid from fortified food or as a supplement consumed with food = 0.5 μg of a supplement taken on an empty stomach. gAlthough AIs have been set for choline, there are few data to assess whether a dietary supply of choline is needed at all stages of the life cycle, and it may be that the choline requirement can be met by endogenous synthesis at some of these stages. hBecause 10 to 30 percent of older people may malabsorb food-bound B12, it is advisable for those older than 50 years to meet their RDA mainly by consuming foods fortified with B12 or a supplement containing B12. iIn view of evidence linking folate intake with neural tube defects in the fetus, it is recommended that all women capable of becoming pregnant consume 400 μg from supplements or fortified foods in addition to intake of food folate from a varied diet. jIt is assumed that women will continue consuming 400 μg from supplements or fortified food until their pregnancy is confirmed and they enter prenatal care, which ordinarily occurs after the end of the periconceptional period—the critical time for formation of the neural tube. SOURCE: IOM (1997, 1998, 2000b, 2001). |
|||||||
TABLE C-3 Dietary Reference Intakes: Recommended Intakes for Individuals, Elements
|
Magnesium (mg/d) |
Manganese (mg/d) |
Molybdenum (μg/d) |
Phosphorus (mg/d) |
Selenium (μg/d) |
Zinc (mg/d) |
|
|
|||||
|
30* |
0.003* |
2* |
100* |
15* |
2* |
|
75* |
0.6* |
3* |
275* |
20* |
3 |
|
|
|||||
|
80 |
1.2* |
17 |
460 |
20 |
3 |
|
130 |
1.5* |
22 |
500 |
30 |
5 |
|
|
|||||
|
240 |
1.9* |
34 |
1,250 |
40 |
8 |
|
410 |
2.2* |
43 |
1,250 |
55 |
11 |
|
400 |
2.3* |
45 |
700 |
55 |
11 |
|
420 |
2.3* |
45 |
700 |
55 |
11 |
|
420 |
2.3* |
45 |
700 |
55 |
11 |
|
420 |
2.3* |
45 |
700 |
55 |
11 |
|
|
|||||
|
240 |
1.6* |
34 |
1,250 |
40 |
8 |
|
360 |
1.6* |
43 |
1,250 |
55 |
9 |
|
310 |
1.8* |
45 |
700 |
55 |
8 |
|
320 |
1.8* |
45 |
700 |
55 |
8 |
|
320 |
1.8* |
45 |
700 |
55 |
8 |
|
320 |
1.8* |
45 |
700 |
55 |
8 |
|
|
|||||
|
400 |
2.0* |
50 |
1,250 |
60 |
12 |
|
350 |
2.0* |
50 |
700 |
60 |
11 |
|
360 |
2.0* |
50 |
700 |
60 |
11 |
|
|
|||||
|
360 |
2.6* |
50 |
1,250 |
70 |
13 |
|
310 |
2.6* |
50 |
700 |
70 |
12 |
|
320 |
2.6* |
50 |
700 |
70 |
12 |
|
SOURCE: IOM (1997, 2000b, 2001). |
|||||
TABLE C-4 Dietary Reference Intakes: Recommended Intakes for Individuals, Macronutrients
|
Life Stage Group |
Carbohydrate (g/d) |
Total Fiber (g/d) |
Fat (g/d) |
Linoleic Acid (g/d) |
α-Linolenic Acid (g/d) |
Proteina (g/d) |
|
Infants |
|
|||||
|
0–6 mo |
60* |
ND |
31* |
4.4* |
0.5* |
9.1* |
|
7–12 mo |
95* |
ND |
30* |
4.6* |
0.5* |
13.5 |
|
Children |
|
|||||
|
1–3 y |
130 |
19* |
ND |
7* |
0.7* |
13 |
|
4–8 y |
130 |
25* |
ND |
10* |
0.9* |
19 |
|
Males |
|
|||||
|
9–13 y |
130 |
26* |
ND |
12* |
1.2* |
34 |
|
14–18 y |
130 |
38* |
ND |
16* |
1.6* |
52 |
|
19–30 y |
130 |
38* |
ND |
17* |
1.6* |
56 |
|
31–50 y |
130 |
38* |
ND |
17* |
1.6* |
56 |
|
51–70 y |
130 |
30* |
ND |
14* |
1.6* |
56 |
|
> 70 y |
130 |
30* |
ND |
14* |
1.6* |
56 |
|
Females |
|
|||||
|
9–13 y |
130 |
31* |
ND |
10* |
1.0* |
34 |
|
14–18 y |
130 |
26* |
ND |
11* |
1.1* |
46 |
|
19–30 y |
130 |
25* |
ND |
12* |
1.1* |
46 |
|
31–50 y |
130 |
25* |
ND |
12* |
1.1* |
46 |
|
51–70 y |
130 |
21* |
ND |
11* |
1.1* |
46 |
|
> 70 y |
130 |
21* |
ND |
11* |
1.1* |
46 |
|
Pregnancy |
|
|||||
|
14–18 y |
175 |
28* |
ND |
13* |
1.4* |
71 |
|
19–30 y |
175 |
28* |
ND |
13* |
1.4* |
71 |
|
31–50 y |
175 |
28* |
ND |
13* |
1.4* |
71 |
|
Lactation |
|
|||||
|
14–18 y |
210 |
29* |
ND |
13* |
1.3* |
71 |
|
19–30 y |
210 |
29* |
ND |
13* |
1.3* |
71 |
|
31–50 y |
210 |
29* |
ND |
13* |
1.3* |
71 |
|
NOTE: This table presents Recommended Dietary Allowances (RDAs) in bold type and Adequate Intakes (AIs) in ordinary type followed by an asterisk (*). RDAs and AIs may both be used as goals for individual intake. RDAs are set to meet the needs of almost all (97 to 98 percent) individuals in a group. For healthy infants fed human milk, the AI is the mean intake. The AI for other life stage and gender groups is believed to cover needs of all individuals in the group, but lack of data or uncertainty in the data prevents being able to specify with confidence the percentage of individuals covered by this intake. aBased on 0.8 g protein/kg body weight for reference body weight. SOURCE: IOM (2002a). |
||||||
TABLE C-5 Acceptable Macronutrient Distribution Ranges
|
|
Range (% of energy) |
||
|
Macronutrient |
Children, 1–3 y |
Children, 4–18 y |
Adults |
|
Fat |
30–40 |
25–35 |
20–35 |
|
n-6 polyunsaturated fats (linoleic acid) |
5–10 |
5–10 |
5–10 |
|
n-3 polyunsaturated fatsa (α-linolenic acid) |
0.6–1.2 |
0.6–1.2 |
0.6–1.2 |
|
Carbohydrate |
45–65 |
45–65 |
45–65 |
|
Protein |
5–20 |
10–30 |
10–35 |
|
aApproximately 10% of the total can come from longer-chain n-3 fatty acids. SOURCE: IOM (2002a). |
|||
TABLE C-6 Dietary Reference Intakes: Tolerable Upper Intake Levels (ULa), Vitamins
|
Life Stage Group |
Vitamin A (μg/d)b |
Vitamin C (mg/d) |
Vitamin D (μg/d) |
Vitamin K |
Thiamin |
|
|
Infants |
|
|||||
|
0–6 mo |
600 |
NDf |
25 |
ND |
ND |
ND |
|
7–12 mo |
600 |
ND |
25 |
ND |
ND |
ND |
|
Children |
|
|||||
|
1–3 y |
600 |
400 |
50 |
200 |
ND |
ND |
|
4–8 y |
900 |
650 |
50 |
300 |
ND |
ND |
|
Males, Females |
|
|||||
|
9–13 y |
1,700 |
1,200 |
50 |
600 |
ND |
ND |
|
14–18 y |
2,800 |
1,800 |
50 |
800 |
ND |
ND |
|
19–70 y |
3,000 |
2,000 |
50 |
1,000 |
ND |
ND |
|
> 70 y |
3,000 |
2,000 |
50 |
1,000 |
ND |
ND |
|
Pregnancy |
|
|||||
|
14–18 y |
2,800 |
1,800 |
50 |
800 |
ND |
ND |
|
19–50 y |
3,000 |
2,000 |
50 |
1,000 |
ND |
ND |
|
Lactation |
|
|||||
|
14–18 y |
2,800 |
1,800 |
50 |
800 |
ND |
ND |
|
19–50 y |
3,000 |
2,000 |
50 |
1,000 |
ND |
ND |
|
aUL = The maximum level of daily nutrient intake that is likely to pose no risk of adverse effects. Unless otherwise specified, the UL represents total intake from food, water, and supplements. Due to lack of suitable data, ULs could not be established for vitamin K, thiamin, riboflavin, vitamin B12, pantothenic acid, biotin, or carotenoids. In the absence of ULs, extra caution may be warranted in consuming levels above recommended intakes. bAs preformed vitamin A only. cAs α-tocopherol; applies to any form of supplemental α-tocopherol. |
||||||
|
Riboflavin |
Niacin (mg/d)d |
Vitamin B6 (mg/d) |
Folate (μg/d)d |
Vitamin B12 |
Pantothenic Acid |
Biotin |
Choline (g/d) |
Carotenoidse |
|
|
||||||||
|
ND |
ND |
ND |
ND |
ND |
ND |
ND |
ND |
ND |
|
ND |
ND |
ND |
ND |
ND |
ND |
ND |
ND |
ND |
|
|
||||||||
|
ND |
10 |
30 |
300 |
ND |
ND |
ND |
1.0 |
ND |
|
ND |
15 |
40 |
400 |
ND |
ND |
ND |
1.0 |
ND |
|
|
||||||||
|
ND |
20 |
60 |
600 |
ND |
ND |
ND |
2.0 |
ND |
|
ND |
30 |
80 |
800 |
ND |
ND |
ND |
3.0 |
ND |
|
ND |
35 |
100 |
1,000 |
ND |
ND |
ND |
3.5 |
ND |
|
ND |
35 |
100 |
1,000 |
ND |
ND |
ND |
3.5 |
ND |
|
|
||||||||
|
ND |
30 |
80 |
800 |
ND |
ND |
ND |
3.0 |
ND |
|
ND |
35 |
100 |
1,000 |
ND |
ND |
ND |
3.5 |
ND |
|
|
||||||||
|
ND |
30 |
80 |
800 |
ND |
ND |
ND |
3.0 |
ND |
|
ND |
35 |
100 |
1,000 |
ND |
ND |
ND |
3.5 |
ND |
|
dThe ULs for vitamin E, niacin, and folate apply to synthetic forms obtained from supplements, fortified foods, or a combination of the two. eβ-Carotene supplements are advised only to serve as a provitamin A source for individuals at risk of vitamin A deficiency. fND = Not determinable due to lack of data of adverse effects in this age group and concern with regard to lack of ability to handle excess amounts. Source of intake should be from food only to prevent high levels of intake. SOURCE: IOM (1997, 1998, 2000b, 2001). |
||||||||
TABLE C-7 Dietary Reference Intakes: Tolerable Upper Intake Levels (ULa), Elements
|
Life Stage Group |
Arsenicb |
Boron (mg/d) |
Calcium (g/d) |
Chromium |
Copper (μg/d) |
Fluoride (mg/d) |
Iodine (μg/d) |
Iron (mg/d) |
|
Infants |
|
|||||||
|
0–6 mo |
NDf |
ND |
ND |
ND |
ND |
0.7 |
ND |
40 |
|
7–12 mo |
ND |
ND |
ND |
ND |
ND |
0.9 |
ND |
40 |
|
Children |
|
|||||||
|
1–3 y |
ND |
3 |
2.5 |
ND |
1,000 |
1.3 |
200 |
40 |
|
4–8 y |
ND |
6 |
2.5 |
ND |
3,000 |
2.2 |
300 |
40 |
|
Males, Females |
|
|||||||
|
9–13 y |
ND |
11 |
2.5 |
ND |
5,000 |
10 |
600 |
40 |
|
14–18 y |
ND |
17 |
2.5 |
ND |
8,000 |
10 |
900 |
45 |
|
19–70 y |
ND |
20 |
2.5 |
ND |
10,000 |
10 |
1,100 |
45 |
|
> 70 y |
ND |
20 |
2.5 |
ND |
10,000 |
10 |
1,100 |
45 |
|
Pregnancy |
|
|||||||
|
14–18 y |
ND |
17 |
2.5 |
ND |
8,000 |
10 |
900 |
45 |
|
19–50 y |
ND |
20 |
2.5 |
ND |
10,000 |
10 |
1,100 |
45 |
|
Lactation |
|
|||||||
|
14–18 y |
ND |
17 |
2.5 |
ND |
8,000 |
10 |
900 |
45 |
|
19–50 y |
ND |
20 |
2.5 |
ND |
10,000 |
10 |
1,100 |
45 |
|
aUL = The maximum level of daily nutrient intake that is likely to pose no risk of adverse effects. Unless otherwise specified, the UL represents total intake from food, water, and supplements. Due to lack of suitable data, ULs could not be established for arsenic, chromium, and silicon. In the absence of ULs, extra caution may be warranted in consuming levels above recommended intakes. bAlthough the UL was not determined for arsenic, there is no justification for adding arsenic to food or supplements. cThe ULs for magnesium represent intake from a pharmacological agent only and do not include intake from food and water. dAlthough silicon has not been shown to cause adverse effects in humans, there is no justification for adding silicon to supplements. |
||||||||
|
Magnesium (mg/d)c |
Manganese (mg/d) |
Molybdenum (μg/d) |
Nickel (mg/d) |
Phosphorus (g/d) |
Selenium (μg/d) |
Silicond |
Vanadium (mg/d)e |
Zinc (mg/d) |
|
|
||||||||
|
ND |
ND |
ND |
ND |
ND |
45 |
ND |
ND |
4 |
|
ND |
ND |
ND |
ND |
ND |
60 |
ND |
ND |
5 |
|
|
||||||||
|
65 |
2 |
300 |
0.2 |
3 |
90 |
ND |
ND |
7 |
|
110 |
3 |
600 |
0.3 |
3 |
150 |
ND |
ND |
12 |
|
|
||||||||
|
350 |
6 |
1,100 |
0.6 |
4 |
280 |
ND |
ND |
23 |
|
350 |
9 |
1,700 |
1.0 |
4 |
400 |
ND |
ND |
34 |
|
350 |
11 |
2,000 |
1.0 |
4 |
400 |
ND |
1.8 |
40 |
|
350 |
11 |
2,000 |
1.0 |
3 |
400 |
ND |
1.8 |
40 |
|
|
||||||||
|
350 |
9 |
1,700 |
1.0 |
3.5 |
400 |
ND |
ND |
34 |
|
350 |
11 |
2,000 |
1.0 |
3.5 |
400 |
ND |
ND |
40 |
|
|
||||||||
|
350 |
9 |
1,700 |
1.0 |
4 |
400 |
ND |
ND |
34 |
|
350 |
11 |
2,000 |
1.0 |
4 |
400 |
ND |
ND |
40 |
|
eAlthough vanadium in food has not been shown to cause adverse effects in humans, there is no justification for adding vanadium to food and vanadium supplements should be used with caution. The UL is based on adverse effects in laboratory animals and this data could be used to set a UL for adults but not children and adolescents. fND = Not determinable due to lack of data of adverse effects in this age group and concern with regard to lack of ability to handle excess amounts. Source of intake should be from food only to prevent high levels of intake. SOURCE: IOM (1997, 2000b, 2001). |
||||||||
TABLE C-8 Additional Macronutrient Recommendations
|
Macronutrient |
Recommendation |
|
Dietary cholesterol |
As low as possible while consuming a nutritionally adequate diet |
|
Trans fatty acids |
As low as possible while consuming a nutritionally adequate diet |
|
Saturated fatty acids |
As low as possible while consuming a nutritionally adequate diet |
|
Added sugars |
Limit to no more than 25% of total energy |
|
SOURCE: IOM (2002a). |
|
TABLE C-9 Reference Values for Nutrition Labeling, Based on a 2,000-Calorie Intake, for Adults and Children 4 or More Years of Age